Expression of p53, Bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 42, Issue 3, 2001, Pages 481-489

  Invernizzi, R ^a   Pecci, A ^a   Bellotti, L ^a   Ascari, E ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute leukaemia; Apoptosis; Immunocytochemistry; MDS; Myelodysplastic syndrome; Oncoproteins

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL SURVIVAL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 0034907741     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109064605     Document Type: Article

References (46)

1. Constitutive c-myc expression in IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis
2. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
3. The fas death factors
4. Mechanisms of apoptotic cell death
5. Cellular oncogenes in neoplasia
6. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A leukemia intergroup pilot study
7. Cytokines, molecular biological abnormalities, and acute myelogenous leukemia
8. p53 is required for radiation-induced apoptosis in mouse thymocytes
9. The bcl-2 gene: Prototype of a gene family that controls programmed cell death (apoptosis)
10. Induction of apoptosis by a dominant negative H-ras mutant (116y) in K562 cells
11. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks G1 arrest
12. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
13. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
14. The molecular pathophysiology of myeloid leukaemias: Ras revisited
15. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis
16. Bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis
17. Apoptosis in myelodysplasia: A paradox or paradigm
18. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
19. Incidence and role of apoptosis in myelodysplastic syndrome: Morphological and ultrastructural assessment
20. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin
21. The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies
22. Apoptosis and its significance in MDS: Controversies revisited
23. A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies
24. Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment
25. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes
26. In situ apoptotic cell labeling by the TUNEL method: Improvement and evaluation on cell preparations
27. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syodrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia
28. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up
29. Mutation of the p53 gene in human acute myelogenous leukemia
30. Mutations of the p53 gene in acute myeloid leukemia
31. N-ras gene point mutations in Brazilian acute myelogenous leukemia patient correlate with a poor prognosis
32. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia
33. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice
34. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
35. Expression of apoptosis-controlling proteins in acute leukemia cells
36. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia
37. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
38. Bcl-2 expression in acute myeloblastic leukaemia: Relationship with autonomous growth and CD34 antigen expression
39. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate
40. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
41. Biologic characteristics of 164 patients with myelodysplastic syndromes
42. "Low-risk" myelodysplastic syndrome is associated with excessive apoptosis and and increased ratio of pro-versus anti-apoptotic bcl-2-related proteins
43. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Immunostaining of bone marrow biopsies
44. Mutations in the p53 gene in myelodysplastic syndromes
45. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes
46. Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: Aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia